ResVita Bio Receives NIH Grant to Develop Breakthrough Treatment for Severe Atopic Dermatitis

BERKELEY, Calif., Sept. 18, 2023 /PRNewswire/ — ResVita Bio, a synthetic biology startup, announces that it has been awarded a $250,000 Phase 1 Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Disease (NIAID). This grant will be used to…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.